Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

NCT06439056 · Completed

Last updated 2026-05-28

This clinical trial tests how a new investigational drug, NEX-22A, affects the levels of liraglutide in the body when given in increasing doses to adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 12 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-05 · est. completion 2025-07

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06439056 ↗

Description as written by the study sponsor.

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

Treatments tested

NEX-22A, a prolonged release formulation of liraglutide Drug

NEX-22A, a prolonged release formulation of liraglutide

Main thing measured	To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes
Sponsor	Nanexa AB
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06439056 ↗